Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality

Clin Infect Dis. 2021 Dec 6;73(11):2116-2118. doi: 10.1093/cid/ciab409.

Abstract

Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760-51 530).

Keywords: COVID-19; IL-6 inhibitors; cost-effectiveness; health economics; tocilizumab.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19 Drug Treatment*
  • Cost-Benefit Analysis
  • Dexamethasone / therapeutic use
  • Humans
  • Quality-Adjusted Life Years
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Dexamethasone
  • tocilizumab